# A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

> **NCT04052932** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 594 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** SHR4640 dose1
- **DRUG:** SHR4640 dose2
- **DRUG:** Placebo oral tablet
- **DRUG:** Allopurinol 300 MG

## Key facts

- **NCT ID:** NCT04052932
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-16
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 594 (ACTUAL)
- **Last updated:** 2022-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04052932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04052932, "A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04052932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*